/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Immix Biopharma Inc Share Price Today: Live Updates & Key Insights

Immix Biopharma Inc share price today is $10.14, up -3.35%. The stock opened at $10.54 against the previous close of $10.46, with an intraday high of $10.54 and low of $9.9.

Immix Biopharma Inc Share Price Chart

style
pb-0

Immix Biopharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Immix Biopharma Inc Share Price Performance

$10.14 -0.0335(-3.35%) IMMX at 13 Mar 2026 01:38 PM Biotechnology
Lowest Today 9.9
Highest Today 10.54
Today’s Open 10.54
Prev. Close 10.46
52 Week High 10.71
52 Week Low 1.34
Day’s Range: Low 9.9 High 10.54
52-Week Range: Low 1.34 High 10.71
1 day return -
1 Week return +9.13
1 month return +39.13
3 month return +63.44
6 month return +383.33
1 year return +518.9
3 year return +467.03
5 year return +175.81
10 year return -

Immix Biopharma Inc Institutional Holdings

Saturn V Capital Management LLC 5.66

Eventide Asset Management, LLC 4.81

Eventide Healthcare & Life Sciences I 4.81

Adage Capital Partners Gp LLC 2.83

Vanguard Group Inc 2.07

Bleichroeder LP 1.89

Blue Owl Capital Holdings LP 1.86

Vanguard Total Stock Mkt Idx Inv 1.29

Franklin Biotechnology Discv A(acc)USD 1.18

HR SICAV - Global Quant Equits - (GBP) A 0.79

Franklin Biotechnology Discovery A 0.67

Burkehill Global Management, LP 0.56

Renaissance Technologies Corp 0.49

Vanguard Institutional Extnd Mkt Idx Tr 0.46

KVP Capital Advisors, LP 0.44

Geode Capital Management, LLC 0.35

IMC US Ultra Micro Cap 0.28

LGT Fund Management Company Ltd 0.24

The Informed Momentum Company (formerly EAM Investors) 0.23

Morgan Stanley - Brokerage Accounts 0.23

J. Goldman & Co LP 0.22

Fidelity Extended Market Index 0.22

State Street Corp 0.19

Susquehanna International Group, LLP 0.17

Citadel Advisors Llc 0.17

Northern Trust Corp 0.17

Omers Administration Corp 0.14

Pleiades Small Cap Equity A 0.14

United Capital Financial Advisers Inc 0.13

Blackrock Extended Mkt Fund CF 0.12

Timber Point Global Allocations Instl 0.11

Extended Equity Market Fund K 0.10

iShares Micro-Cap ETF 0.10

Fidelity Total Market Index 0.07

Spartan Extended Market Index Pool F 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

Fidelity Series Total Market Index 0.05

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

Immix Biopharma Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Immix Biopharma Inc Fundamentals

Market Cap 553.91 M

PB Ratio 67.0191

PE Ratio 0.0

Enterprise Value 539.07 M

Total Assets 22.95 M

Volume 618734

Immix Biopharma Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:-89517000 -89.5M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:-89517000 -89.5M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-14136381 -14.1M, FY22:-8229713 -8.2M, FY21:-24383879 -24.4M, FY20:-1147863 -1.1M, FY19:-972811 -1.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-79835 -0.1M, Q1/2025:-59180 -0.1M, Q3/2024:null 0.0M, Q2/2024:-24295 -0.0M

Quarterly Net worth Q3/2025:-7585692 -7.6M, Q2/2025:-6622563 -6.6M, Q1/2025:-4542528 -4.5M, Q3/2024:-7149395 -7.1M, Q2/2024:-4392936 -4.4M

About Immix Biopharma Inc & investment objective

Company Information Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Organisation Biotechnology

Employees 18

Industry Biotechnology

CEO Dr. Ilya Rachman M.B.A., M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow